BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI ® ...
Results from the Phase 3 part of AMETHYST are expected in the first half of 2027; in January 2026 the FDA granted ...
In 2025, the AAP updated its guidance to recommend exome or genome sequencing as a first-tier test for children with global ...
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein ...
CONSHOHOCKEN, Pa.-- (BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the ...
Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with ...
Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H ...
Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival ...
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager . Agreement also gives Novartis ...
Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as ...
CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 ...
Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results